USRE44459EExpiredUtilityPatentIndex 57
Method for lowering blood glucose
Est. expirySep 5, 2009(expired)· nominal 20-yr term from priority
A61K 9/2027A61K 9/0004A61K 9/2054A61K 31/64A61K 9/2031A61P 3/10
57
PatentIndex Score
2
Cited by
33
References
3
Claims
Abstract
The invention disclosed comprises a method for administering the antidiabetic drug glipizide to a patient in need of glipizide in need of antidiabetic therapy.
Claims
exact text as granted — not AI-modifiedWe claim:
1. A method for treating hyperglycemia in a patient, wherein the method comprises administering to the patient a dosage form comprising 2.0 mg to 750 mg of a glipizide composition that is administered at a dose of 10 ng to 25 mg per hour over an extended period of 24 hours, and wherein the method is characterized by administering the glipizide from a dosage form selected from the group consisting of an osmotic dosage form comprising a semipermeable polymer permeable to the passage of fluid, and a diffusion dosage form comprising a polymer that permits diffusion of glipizide through the polymer.
2. A method for lowering blood sugar in the treatment of a diabetic patient, which method comprises orally administering to the patient an effective blood sugar lowering dose of a composition comprising glipizide and a pharmaceutically acceptable carrier, which blood sugar lowering dose is administered by a method selected from the group consisting of osmosis comprising a semipermeable membrane, diffusion through a polymer permeable to glipizide, and ion-exchange over time to produce the intended lowering of the blood sugar in the patient.
3. A method for treating hyperglycemia in a patient, wherein the method comprises orally administering to the patient a once-a-day dosage form comprising 2.0 mg to 50 mg of a glipizide composition and wherein the method is characterized by administering the glipizide from an osmotic dosage form comprising polyethylene oxide, hydroxypropylmethylcellulose, cellulose acetate, and sodium chloride.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.